India I Equities

Building Materials Company Update

11 June 2021

Century Plyboards

Good Q4, large capex in MDF planned over FY21-23; retaining a Hold

Strong volumes in ply/laminates/MDF, price hikes, low-cost inventory (laminate) and cost-control aided Century's Q4 revenue (up 41% y/y) and margins (17.2%). Its net-cash status and FCFs were other positives. Healthy double-digit growth and high margins will persist, per management. Huge capex (Rs7bn) is planned over FY21-23 mainly to augment MDF capacity. While we like Century for its leading positions across wood-panel categories, healthy FCFs and improving financials (22%/32% revenue/PAT CAGRs over FY21-23 after a flattish FY16-21), at 26x FY23e P/E, we see low margin of safety. Our new TP is Rs444 (28x FY23e P/E, the five-year mean). Growth/margins across segments and the MDF capacity expansion are key monitorables.

Q4, the best quarter. Revenue/EBITDA/PAT grew 41%/81%/115% y/y on strong volumes, better pricing across segments and cost-reduction steps. Despite RM cost pressure, the EBITDA margin held high (17.2%) and will continue on the various measures taken. Also, net-cash status was achieved.

Strong volumes across segments. Ply/laminate/MDF revenues were driven by good volumes (up 39%/38%/24% y/y) and better pricing. These, along with cost controls and operating leverage aided the healthy EBITDA margin (Century/ply/laminate/MDF: 17.2%/12.8%/22.3%/26.8%). The high Q4 laminate margin will return to the normal 16-18%, per management.

Large capex in MDF. The Rs7bn capex over FY21-23 (to be funded by internal accruals) will be mainly in MDF (Rs2.5bn in Punjab for 400cbm by Q4 FY22, Rs5bn in AP for 700cbm by Q4 FY23). Ply/laminate capacities will increase by line balancing and adding a few machines. Face-veneer production at Gabon started in Feb'21 and will be used in the economy plywood range.

Robust outlook largely priced in. After a flattish FY16-21, we expect 22%/30%/32% CAGRs in revenue/EBITDA/adj. PAT over FY21-23 driven by growth/margin-expansion across segments, healthy FCFs and a ~20% RoE. At 26x FY23e P/E, we see low margin of safety.

Key financials (YE Mar)	FY19	FY20	FY21	FY22e	FY23e
Sales (Rsm)	22,804	23,170	21,304	27,147	31,664
Net profit (Rsm)	1,485	1,506	1,910	2,984	3,530
EPS (Rs)	7	7	9	13	16
P/E (x)	63	62	49	31	26
EV / EBITDA (x)	32	29	27	19	16
P/BV (x)	10	9	7	6	5
RoE (%)	15	14	15	20	19
RoCE (%)after tax	12	14	15	19	18
Dividend yield (%)	0	0	-	0	0
Net debt / equity (x)	0	0	(0)	(0)	(0)
Source: Company, Anand Rathi Resea	arch				

Rating: **Hold**Target Price: Rs444
Share Price: Rs418

CPBI IN / CNTP.BO
Rs447 / 101
52475 / 15799
\$1.9m
Rs93bn / \$1273.3m
222m

Shareholding pattern (%)	Mar'21	Dec'20	Sep'20
Promoters	73.0	73.0	73.1
- of which, Pledged	-	-	-
Free float	27.0	27.0	27.0
- Foreign institutions	4.8	4.7	5.9
- Domestic institutions	12.4	12.1	10.6
- Public	9.8	10.2	10.5

Estimates revision (%)	FY22e	FY23e
Sales	3	5
EBITDA	4	7
PAT	2	3



Source: Bloomberg

Ashish Poddar Research Analyst +9122 66266407 ashishpoddar@rathi.com

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

Fig 2 - Balance sheet (Rs m)

Quick Glance - Financials and Valuations (Consol.)

Year-end: Mar

Share capital

Fig 1 – Income statement (Rsm)						
Year-end: Mar	FY19	FY20	FY21	FY22e	FY23e	
Net revenues	22,804	23,170	21,304	27,147	31,664	
Growth (%)	12.7	1.6	(8.1)	27.4	16.6	
Direct costs	11,509	11,605	10,405	13,192	15,381	
SG&A	8,279	8,258	7,543	9,201	10,615	
EBITDA	3,016	3,307	3,355	4,755	5,668	
EBITDA margins (%)	13.2	14.3	15.7	17.5	17.9	
- Depreciation	595	763	687	731	908	
Other income	71	128	173	125	145	
Interest expenses	469	389	128	130	153	
PBT	2,023	1,772	2,596	4,019	4,752	
Effective tax rates (%)	26.4	29.3	26.3	25.5	25.5	
+ Associates / (Minorities)	-	-	-	-	-	
Net income	1,485	1,506	1,910	2,984	3,530	
Adjusted income	1,485	2,017	2,028	2,984	3,530	
WANS	223	223	223	223	223	
FDEPS (Rs / sh)	6.7	6.8	8.6	13.4	15.9	
FDEPS growth (%)	(10.6)	1.4	26.8	56.3	18.3	
Gross margins (%)	49.5	49.9	51.2	51.4	51.4	

Net worth	9,749	10,906	12,674	15,213	18,298
Debt	4,816	2,574	1,288	1,488	1,688
Minority interest	253	(17)	(12)	(10)	(8)
DTL / (Assets)	12	5	1	1	1
Capital employed	14,830	13,468	13,951	16,692	19,979
Net tangible assets	8,348	7,764	7,538	9,607	11,699
Net intangible assets	16	22	20	20	20
Goodwill	-	-	-	-	-
CWIP (tang. &intang.)	268	160	285	485	685
Investments (strategic)	-	-	-	-	-
Investments (financial)	64	63	1,169	1,569	1,819
Current assets (ex cash)	9,159	8,344	8,195	8,562	9,758
Cash	262	248	908	878	921
Current liabilities	3,288	3,132	4,165	4,429	4,923
Working capital	5,870	5,211	4,030	4,133	4,835
Capital deployed	14,830	13,468	13,951	16,692	19,979
Contingent liabilities	435	706	-	-	-
Fig 4 – Ratio analysis					
Year-end: Mar		Y19 FY	′20 FY21	FY22e	FY23e
D/F (v)		527 6	10 /07	21.2	26.3

FY20

223

FY22e

223

223

FY23e

223


Fig 3 – Cash-flow statement (Rsm)							
Year-end: Mar	FY19	FY20	FY21	FY22e	FY23e		
EBIT (excluding other income)	2,565	2,806	2,716	4,013	4,747		
+ Non-cash items	595	763	687	731	908		
Oper. prof. before WC	3,160	3,569	3,402	4,744	5,655		
- Incr. / (decr.) in WC	22	(793)	(755)	97	697		
Others incl. taxes	480	362	452	1,027	1,212		
Operating cash-flow	2,658	4,001	3,705	3,620	3,746		
- Capex (tang. + intang.)	1,636	1,219	639	3,000	3,200		
Free cash-flow	1,022	2,782	3,066	620	546		
Acquisitions	-	-	-	-	-		
- Div.(incl. buyback & taxes)	268	535	0	445	445		
+ Equity raised	-	-	-	-	-		
+ Debt raised	(512)	(2,838)	(1,273)	200	200		
- Fin investments	(63)	(969)	1,202	400	250		
- Misc. (CFI + CFF)	276	396	547	5	8		
Net cash-flow	29	(18)	44	(31)	43		
Source: Company, Anand Rathi Rese	earch						

Fig 4 – Ratio analysis					
Year-end: Mar	FY19	FY20	FY21	FY22e	FY23e
P/E (x)	62.7	61.8	48.7	31.2	26.3
EV / EBITDA (x)	32.3	28.8	27.5	19.4	16.2
EV / Sales (x)	4.3	4.1	4.3	3.4	2.9
P/B (x)	9.5	8.5	7.3	6.1	5.1
RoE (%)	15.2	13.8	15.1	19.6	19.3
RoCE (%) - after tax	12.4	14.0	15.0	18.5	18.3
RoIC	12.9	13.6	15.9	21.4	21.0
DPS (Rs / sh)	1.0	1.0	-	2.0	2.0
Dividend yield (%)	0.2	0.2	-	0.5	0.5
Dividend payout (%) - incl. DDT	15.0	14.8	-	14.9	12.6
Net debt / equity (x)	0.4	0.2	(0.1)	(0.1)	(0.1)
Receivables (days)	47	40	52	40	40
Inventory (days)	74	63	63	55	55
Payables (days)	26	24	36	30	30
CFO: PAT %	179	198	183	121	106
Source: Company, Anand Rathi Research	ch				





Fig 6 - Q4FY21 revenue break-up



Source: Company

Financial highlights

Fig 7 – Financials (standalone)										
(Rs m)	Q4 FY20	Q1 FY21	Q2 FY21	Q3 FY21	Q4 FY21	% Y/Y	% Q/Q	FY21	FY20	% Y/Y
Income	5,242	2,007	5,198	6,544	7,386	41	13	21,135	22,827	(7)
RM costs	2,563	946	2,610	3,282	3,757	47	14	10,594	11,483	(8)
Employee costs	866	566	764	850	1,003	16	18	3,183	3,441	(8)
Other expenses	1,112	487	966	1,193	1,358	22	14	4,004	4,405	(9)
EBITDA	701	8	859	1,218	1,268	81	4	3,354	3,497	(4)
Depreciation	163	143	162	162	159	(2)	(2)	626	676	(7)
Finance costs	83	50	18	11	29	(65)	169	108	372	(71)
Other income	1	46	12	12	37	3,120	210	107	111	(3)
Exceptional items	-	-	-	(118)	-			(118)	(456)	(74)
PBT	456	(139)	691	939	1,117	145	19	2,608	2,104	24
Tax	69	(54)	176	280	284	315	1	688	522	32
PAT	388	(85)	514	659	832	115	26	1,921	1,582	21
EPS (calculated) (Rs)	1.7	(0.4)	2.3	3.0	3.7	115	26	8.6	7.1	21
As % of income						bps y/y	bps q/q			bps y/y
Gross margins	51.1	52.9	49.8	49.9	49.1	(198)	(72)	49.9	49.7	18
Employee costs	16.5	28.2	14.7	13.0	13.6	(295)	58	15.1	15.1	(2)
Other expenses	21.2	24.3	18.6	18.2	18.4	(283)	15	18.9	19.3	(35)
EBITDA margins	13.4	0.4	16.5	18.6	17.2	380	(145)	15.9	15.3	55
Depreciation	3.1	7.1	3.1	2.5	2.2	(95)	(32)	3.0	3.0	0
Finance costs	1.6	2.5	0.3	0.2	0.4	(119)	23	0.5	1.6	(112)
Other income	0.0	2.3	0.2	0.2	0.5	47	32	0.5	0.5	2
PBT	8.7	(6.9)	13.3	16.2	15.1	641	(104)	12.9	11.2	168
Effective tax rate	15.0	38.8	25.5	29.9	25.5	1,046	(439)	26.4	24.8	154
PAT margins	7.4	(4.2)	9.9	10.1	11.3	387	120	9.1	6.9	216
Revenue, by segment (Rs m)						%Y/Y	%Q/Q			%Y/Y
Plywood and allied products	2,792	988	2,680	3,571	3,992	43	12	11,232	12,343	(9)
Laminate and allied products	1,061	403	1,018	1,200	1,529	44	27	4,150	4,633	(10)
Medium-density fibre boards	843	303	935	1,165	1,191	41	2	3,594	3,505	3
Particle boards	231	83	256	262	300	30	15	901	991	(9)
CFS services	204	203	199	209	219	7	5	830	870	(5)
Others	120	32	115	146	166	38	13	459	518	(11)
Revenue mix (%)										
Plywood and allied products	53.2	49.1	51.5	54.5	54.0	80	(53)	53.1	54.0	(93)
Laminate and allied products	20.2	20.0	19.6	18.3	20.7	48	236	19.6	20.3	(66)
Medium-density fibre boards	16.1	15.1	18.0	17.8	16.1	4	(168)	17.0	15.3	165
Particle boards	4.4	4.1	4.9	4.0	4.1	(34)	6	4.3	4.3	(8)
CFS services	3.9	10.1	3.8	3.2	3.0	(93)	(22)	3.9	3.8	12
Others	2.3	1.6	2.2	2.2	2.2	(4)	1	2.2	2.3	(9)
EBITDA margins (%)										
Plywood and allied products	8.5	(9.6)	13.1	15.1	12.8	429	(230)	11.6	12.4	(77)
Laminate and allied products	15.8	4.2	13.5	19.1	22.3	649	320	17.4	13.2	429
Medium-density fibre boards	25.4	7.4	28.1	27.7	26.8	142	(91)	25.8	24.3	149
Particle boards	22.1	9.9	21.6	23.2	18.6	(353)	(454)	20.0	24.9	(488)
CFS services	34.1	34.5	29.6	26.6	27.1	(695)	52	29.4	33.8	(439)
EBIT (Rs m)										
Plywood and Allied Products	219	(77)	342	417	603	175	45	1,285	1,084	19
Laminate and Allied Products	146	2	113	210	371	153	77	696	561	24
Medium Density Fibre Board	164	(25)	213	277	299	82	8	764	670	14
Particle Board	38	1	42	49	47	22	(4)	139	208	(33)
CFS Services	42	42	32	28	33	(22)	17	134	151	(11)
EBIT margins (%)						bps y/y	bps q/q			bps y/y
Plywood and Allied Products	7.9	(7.8)	12.8	11.7	15.1	725	344	11.4	8.8	266
Laminate and Allied Products	13.8	0.5	11.2	17.5	24.2	1,044	677	16.8	12.1	465
Medium Density Fibre Board	19.5	(8.2)	22.8	23.7	25.1	564	137	21.3	19.1	215
Particle Board	16.6	1.4	16.4	18.6	15.6	(100)	(303)	15.4	21.0	(562)
CFS Services	20.5	20.7	15.8	13.4	14.9	(557)	157	16.2	17.4	(125)
Others	(9.9)	(22.8)	16.9	17.8	12.8	2,271	(508)	12.9	4.6	836
Total	11.4	(3.2)	14.7	15.4	18.6	718	322	14.6	11.8	274
Un-allocable (as % revenue)	(1.1)	(1.2)	(1.0)	(0.9)	(3.1)	(196)	(223)	(1.7)	(1.0)	(73)
	Note: Segment E								()	(, 0)

Q4FY21 Concall KTAs

Outlook

- While demand was robust till Mar'21, Covid 2.0 has slowed down the momentum since Apr; it should pick up from Q2
- Management expects CAGRs of 10-15% in ply and 15%+ in laminates over the next five years. MDF revenue will be 3x in three years, with great potential in the long term.

Cost-reduction measures

- Well on track regarding cost-reduction steps advised by the consultant (BCG) especially in its MDF business.
- Key area identified are travel, logistics, supply-chain, channel efficiencies, etc.
- Will also extend to laminates for similar exercises.

Margins, price hikes

- The 23% Q4 laminate margin benefitted from low-cost stocks and price hikes. The 16-18% range, though, is sustainable.
- RM prices in ply were broadly stable while PB (75% pre-laminate mix) was hurt by the steep rise in melamine prices.
- Ply prices raised 2-3% (little scope for more); 3-4% in laminates from Apr'21; very little in MDF

Market-share gains across categories

- *Sainik*, being in the mid-ply segment, gained good market share and has great potential to increase more in coming years from smaller brands/the informal sector.
- Laminate also benefitted from operational issues faced by small non-regulated manufcturers.
- Focus on product launches to fill gaps and on network expansion continues.

MDF

- Sees very high demand; thus, any capacity additions will be absorbed without hurting pricing (unlike in FY19/20).
- Capex at Punjab already begun should be commissioned in Q4 FY22.
 Greenfield unit in AP is in the final stage; likely to be commissioned by Q4 FY23.
- BCG is helping improve efficiencies at plants and in market and through cost rationalization.
- Will continue to look for more capacities in coming years.
- Aspires to be in the 26-28% EBITDA margin range.

Capex

- Targets Rs7bn over FY22 (~Rs2.5bn on MDF Punjab expansion) and FY23 (Rs5bn on MDF AP greenfield project).
- Will add ~30% capacity in ply and ~10% in laminate from line-balancing and adding some machinery.

Face veneer


- The Myanmar plant continues to be faced with disruption from the political unrest. However, it has 2-3 months of stocks.
- Supply from Gabon (Okume grade) can help ease the poor availability issue to some extent


B/Sand CF


- **NWC days** should be stable at ~70. Higher MDF revenue will reduce debtors but will increase inventories.
- Now a net-cash company on strong operating performance and strict working-capital management.


Q4 FY21 Key Highlights


- Q4 was the best quarter, driven by strong ply/laminate volumes and an exceptionally high laminate margin, partially offset by the lower ply margin.
- Ply. Volumes/value up 39%/43% y/y (above ARe); Rs/unit up ~4% q/q and y/y; the EBITDA margin dipped ~200bps q/q to 12.8%.
- Laminates. Volumes/value up 38%/44% y/y (well above ARe); Rs/unit up ~4% q/q and y/y; the EBITDA margin expanded considerably to ~23% on operating leverage as the gross margin was stable q/q.
- **MDF.** Volumes/value up 24%/41% y/y (in-line); Rs/unit up 9% q/q, 14% y/y; EBITDA margin: 27%.
- **PB**. Volumes/value up 11%/30% y/y; Rs/unit up 9% q/q, 18% y/y; EBITDA margin: ~19%
- **CFS.** Volumes/value up 7%/5% y/y; EBITDA margin: 27%.




























Valuation

The building materials sector is faced with several challenges. Yet, we believe in Century's long-term structural growth, supported by macro-economic factors (rising disposable incomes, the government's focus on housing for all, etc.). With its strong brand image (the premium-range Century Club and the mid-range Sainik in plywood) and a diversified product range, it is set to gain from demand revival.

After flattish FY16-21, we expect 22%/30%/32% CAGRs in revenue/EBITDA/adj. PAT over FY21-23, driven by growth/margin-expansion across segments, healthy FCFs and a ~20% RoE.

We like Century Ply for its leading positions across its product categories, strong balance sheet and healthy FCFs. At 26x FY23e P/E, we retain our Hold recommendation on it, at a target price of Rs444 (28x FY23e P/E, the five-year mean), earlier Rs340. Growth/margin recovery across segments and the MDF capacity expansion are key monitorables.

Fig 19 – Change in	estimates					
	Old estimates		New estir	mates	% Var	
(Rs m)	FY22	FY23	FY22	FY23	FY22	FY23
Income	26,310	30,123	27,147	31,664	3	5
EBITDA	4,590	5,282	4,755	5,668	4	7
EBITDA margins %	17.4	17.5	17.5	17.9		
PAT	2,924	3,438	2,984	3,530	2	3
Source: Anand Rathi Research	·h					

Fig 20 – One-year-forward– PE band, Standarddeviation



Risks


- **Slowdown in real-estate activity** will eat into demand for ply-laminate-MDF as home renovations/ purchases are the prime drivers.
- Unfavourable price movement, availability of key raw materials. Sourcing of key raw materials (face veneers, etc.) at reasonable prices is the key challenge due to environmental concerns. Also, a few of the raw materials such as phenol are linked to crude-oil prices, which are volatile. These pose risks to margins.
- Currency volatility. Since the company imports most of its raw material, currency fluctuations could pare its margins.

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 11 June 2021)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps (<us\$1bn)< td=""><td>>25%</td><td>5-25%</td><td><5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No

Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2021. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.